Navigation Links
John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva
Date:7/11/2014

ote collaboration among the world's leading scientific minds and also provide access to the financial and business expertise that can translate cutting-edge research into viable treatments. John Donoghue's leadership in neuroscience and entrepreneurial spirit have proven that he is a global thought leader and the ideal candidate to lead the Center", declares Hansjoerg Wyss, President of the Wyss Foundation.

John P. Donoghue is the founding Chairman of the Department of Neuroscience at Brown, and directs the Brown Institute for Brain Science in Rhode Island, USA (http://brainscience.brown.edu). He will take a one year sabbatical from Brown in 2015 during which he will be devoted to his position as Head of the Wyss Center.

"The biotechnology and life sciences industry is entering a tremendous phase of growth with new discoveries beginning to make their impact globally for human health and well being.

The vision of the Campus and the principles on which the Center is founded create a unique opportunity to help contribute to, and reshape, how we think about biotechnology and life sciences in the context of modern science, business and sustainable development. I am excited to be part of this new initiative, to maximize collaboration, and to join other teams at Campus Biotech to revolutionize the sector." said John P. Donoghue.

John P. Donoghue is one of the most recognised researchers in the neuroengineering field. He has won numerous awards, such as the 2007 KJ Zülch Prize, the highest European distinction for neurological research. He skilfully combines the qualities of a scientist, engineer and manager, for example by coordinating the multidisciplinary team behind the ground-breaking prototype neural interface known as Brain
'/>"/>

SOURCE Campus Biotech
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Taking solar technology up a notch
2. Wysebridge Encourages Taking The Patent Bar Before Major Exam Changes Are Implemented
3. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
4. Shark Branding Corp. CEO Daymond John and Fuse Science CEO Brian Tuffin to be interviewed on Bloomberg Televisions "Taking Stock with Pimm Fox"
5. Waterloo Heights, a Neighborhood Smiles Dental Practice is Taking a Bold New Approach to the Cavity Epidemic
6. Taking a new look at carbon nanotubes
7. Spherix CEO, Anthony Hayes Appears on Bloombergs "Taking Stock With Pimm Fox"
8. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
11. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") ... Opinion on Biological Therapy , Dr. Michael Chopp ... at the Henry Ford Hospital in Detroit, ... has the capacity to promote CNS and peripheral nervous ... to neurological recovery in each case.  They pointed out ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
...
...
Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: